| Patient | Lou Gehrig |
|---|---|
| Date of birth | 1990-06-19 |
| Identifiers | MRN HR-ET018-SYN; SSN (made up) 000-18-6620 |
| Document date | 2026-11-01 |
| Author | Gavin Hollister, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient with progressive weakness and loss of coordination: evaluation for a motor neuron disorder and its mimics, safety, and how he wants to receive results. Concerns: Over about a year he has lost strength and coordination, fumbles with buttons and a bat, trips on curbs, and fell on the ice in the winter, and he wants to know why; He has stopped playing and wants plain answers, delivered to him first; He wants to stay useful and to keep working in some form. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Riluzole 50 mg oral tablet, one tablet by mouth twice daily, an hour before or two hours after meals | One tablet by mouth every 12 hours on an empty stomach | Oral route | 2026-05-18 | active | S |
| Ibuprofen 400 mg oral tablet, one tablet by mouth every 8 hours with food as needed for ankle pain, for up to 5 days | One tablet by mouth every 8 hours with food as needed, up to 5 days | Oral route | 2026-07-20 to 2026-07-25 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Seated spirometry (forced vital capacity) | 2026-05-04 to 2026-05-04 | completed | S |
| MRI of the brain | 2026-05-11 to 2026-05-11 | completed | S |
| MRI of the cervical spine | 2026-05-11 to 2026-05-11 | completed | S |
| Needle electromyography of four body regions | 2026-05-18 to 2026-05-18 | completed | S |
| Motor and sensory nerve conduction studies of the arms and legs | 2026-05-18 to 2026-05-18 | completed | S |
| Genetic testing for ALS-associated genes (SOD1, C9orf72 repeat, FUS, TARDBP and others), with genetic counseling | 2026-05-18 to 2026-05-18 | completed | S |
| Advance care planning conversation, about 30 minutes | 2026-09-21 to 2026-09-21 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-09-21 | Influenza vaccine, 2026-2027 season (inactivated) | completed | S |
| 2026-09-21 | COVID-19 vaccine, 2026-2027 formula | completed | S |
| 2026-09-21 | Hepatitis B vaccine (HepB-CpG), first of two doses | completed | S |
| 2026-10-19 | Hepatitis B vaccine (HepB-CpG), second of two doses | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1938 | Lumbago and a badly jammed thumb during the season | D (CLM-0005) |
| During his playing career | Repeated head injuries, including concussions | D (CLM-0012) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| sister | Died in infancy at about three months; cause not recorded in the cited source | D (CLM-0002) | |
| sister | Died in early childhood of measles, diphtheria and bronchopneumonia | D (CLM-0002) | |
| brother | Died shortly after birth; cause not recorded in the cited source | D (CLM-0002) |
| Concern | Status | Evidence |
|---|---|---|
| Over about a year he has lost strength and coordination, fumbles with buttons and a bat, trips on curbs, and fell on the ice in the winter, and he wants to know why | active | S |
| He has stopped playing and wants plain answers, delivered to him first | active | S |
| He wants to stay useful and to keep working in some form | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 6.8 on 2026-05-04; Hemoglobin [Mass/volume] in Blood 15.2 on 2026-05-04; Platelets [#/volume] in Blood by Automated count 245 on 2026-05-04; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-05-04; Potassium [Moles/volume] in Serum or Plasma 4.4 on 2026-05-04; Creatinine [Mass/volume] in Serum or Plasma 0.88 on 2026-05-04; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 115 on 2026-05-04; Glucose [Mass/volume] in Serum or Plasma 92 on 2026-05-04; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-05-04; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 41 on 2026-07-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 33 on 2026-06-29; Creatine kinase [Enzymatic activity/volume] in Serum or Plasma 412 on 2026-05-04; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 512 on 2026-05-04; Thyrotropin [Units/volume] in Serum or Plasma 1.6 on 2026-05-04; Hemoglobin A1c/Hemoglobin.total in Blood 5.2 on 2026-05-04; Forced vital capacity [Volume] Respiratory system 3.69 on 2026-10-19; FVC measured/predicted 72 on 2026-10-19; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-09-21; Total score [ALSFRS-R] 36 on 2026-10-19; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 2026-10-19; Total score [AUDIT-C] 2 on 2026-09-21 [S]
Strengths and supports: Strengths and supports: disciplined, steady and modest; used to training and working with a team; financially secure; a close household and many friends in the game [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Progressive weakness and loss of coordination for about a year: fumbling with buttons and a bat, tripping on curbs, a fall on the ice in the winter, muscle cramps and twitching in the arms and thighs; no numbness, pain, double vision, or trouble speaking or swallowing. Examination: wasting of the hand muscles (left more than right), fasciculations in both arms and thighs, weakness of grip and of left ankle dorsiflexion, brisk reflexes with spread and a positive Hoffmann sign, normal sensation. Mixed upper and lower motor neuron signs; evaluation for motor neuron disease and its mimics begun, with neuromuscular neurology consultation booked | resolved | confirmed | M62.81 | S — Synthetic presenting problem anchored to his documented decline in 1938 and 1939; superseded by the diagnosis. |
| Amyotrophic lateral sclerosis, limb onset: progressive weakness for about a year with upper and lower motor neuron signs in the cervical and lumbosacral regions, and active and chronic denervation on EMG in the cervical, thoracic and lumbosacral regions with normal sensory nerve conduction; MRI of the brain and cervical spine and blood tests exclude mimics. Meets the Gold Coast criteria and the revised El Escorial category of clinically probable ALS. ALSFRS-R 42 and FVC 88% of predicted at diagnosis. Synthetic modern episode linked to his documented diagnosis | active | confirmed | G12.21 | S — Synthetic modern diagnosis; the documented 1939 diagnosis is the anchor. EMG findings, scores and timing are synthetic. |
| Sprain of the left lateral ankle ligaments after tripping on a curb with left foot drop, while not wearing his ankle-foot orthosis: swelling and tenderness over the anterior talofibular ligament, able to bear weight, no bony tenderness by the Ottawa ankle rules; resolved | resolved | confirmed | S93.402A | S — Synthetic injury; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-04 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-04 | Hemoglobin [Mass/volume] in Blood | 15.2 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 2026-05-04 | Platelets [#/volume] in Blood by Automated count | 245 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-04 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.88 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 115 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-04 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-05-04 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 32 | U/L | 7-55 U/L | Normal | S |
| 2026-05-04 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 10-40 U/L | Normal | S |
| 2026-05-04 | Creatine kinase [Enzymatic activity/volume] in Serum or Plasma | 412 | U/L | 39-308 U/L | High | S |
| 2026-05-04 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 512 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-05-04 | Thyrotropin [Units/volume] in Serum or Plasma | 1.6 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-05-04 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.2 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-05-04 | Forced vital capacity [Volume] Respiratory system | 4.62 | L | >=4.1 L | Normal | S |
| 2026-05-04 | FVC measured/predicted | 90 | % | 80% of predicted or more is normal; noninvasive ventilation is considered below 50% | Normal | S |
| 2026-05-04 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-05-18 | Forced vital capacity [Volume] Respiratory system | 4.52 | L | >=4.1 L | Normal | S |
| 2026-05-18 | FVC measured/predicted | 88 | % | 80% of predicted or more is normal; noninvasive ventilation is considered below 50% | Normal | S |
| 2026-05-18 | Total score [ALSFRS-R] | 42 | {score} | S | ||
| 2026-05-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-06-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 7-55 U/L | Normal | S |
| 2026-06-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 10-40 U/L | Normal | S |
| 2026-06-29 | Forced vital capacity [Volume] Respiratory system | 4.31 | L | >=4.1 L | Normal | S |
| 2026-06-29 | FVC measured/predicted | 84 | % | 80% of predicted or more is normal; noninvasive ventilation is considered below 50% | Normal | S |
| 2026-06-29 | Total score [ALSFRS-R] | 40 | {score} | S | ||
| 2026-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-08-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 35 | U/L | 7-55 U/L | Normal | S |
| 2026-08-24 | Forced vital capacity [Volume] Respiratory system | 4.05 | L | >=4.1 L | Low | S |
| 2026-08-24 | FVC measured/predicted | 79 | % | 80% of predicted or more is normal; noninvasive ventilation is considered below 50% | Low | S |
| 2026-08-24 | Total score [ALSFRS-R] | 38 | {score} | S | ||
| 2026-08-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-10-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 7-55 U/L | Normal | S |
| 2026-10-19 | Forced vital capacity [Volume] Respiratory system | 3.69 | L | >=4.1 L | Low | S |
| 2026-10-19 | FVC measured/predicted | 72 | % | 80% of predicted or more is normal; noninvasive ventilation is considered below 50% | Low | S |
| 2026-10-19 | Total score [ALSFRS-R] | 36 | {score} | S | ||
| 2026-10-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-07-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 7-55 U/L | Normal | S |
| 2026-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-09-21 | Total score [AUDIT-C] | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-04 | Body height | 183 | cm | S |
| 2026-05-04 | Body weight | 89.5 | kg | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 26.7 | kg/m2 | S |
| 2026-05-04 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-05-04 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-05-04 | Heart rate | 68 | /min | S |
| 2026-05-04 | Respiratory rate | 14 | /min | S |
| 2026-05-04 | Body temperature | 36.7 | Cel | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-18 | Body height | 183 | cm | S |
| 2026-05-18 | Body weight | 89.2 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 26.6 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 70 | /min | S |
| 2026-05-18 | Respiratory rate | 14 | /min | S |
| 2026-05-18 | Body temperature | 36.6 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-29 | Body height | 183 | cm | S |
| 2026-06-29 | Body weight | 88.4 | kg | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 26.4 | kg/m2 | S |
| 2026-06-29 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-06-29 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-29 | Heart rate | 72 | /min | S |
| 2026-06-29 | Respiratory rate | 15 | /min | S |
| 2026-06-29 | Body temperature | 36.7 | Cel | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-24 | Body height | 183 | cm | S |
| 2026-08-24 | Body weight | 87.4 | kg | S |
| 2026-08-24 | Body mass index (BMI) [Ratio] | 26.1 | kg/m2 | S |
| 2026-08-24 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-08-24 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-24 | Heart rate | 74 | /min | S |
| 2026-08-24 | Respiratory rate | 16 | /min | S |
| 2026-08-24 | Body temperature | 36.6 | Cel | S |
| 2026-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-10-19 | Body height | 183 | cm | S |
| 2026-10-19 | Body weight | 86.6 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 25.9 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 76 | /min | S |
| 2026-10-19 | Respiratory rate | 16 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-07-20 | Body height | 183 | cm | S |
| 2026-07-20 | Body weight | 88 | kg | S |
| 2026-07-20 | Body mass index (BMI) [Ratio] | 26.3 | kg/m2 | S |
| 2026-07-20 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-07-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-20 | Heart rate | 74 | /min | S |
| 2026-07-20 | Respiratory rate | 15 | /min | S |
| 2026-07-20 | Body temperature | 36.6 | Cel | S |
| 2026-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-21 | Body height | 183 | cm | S |
| 2026-09-21 | Body weight | 87 | kg | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 26 | kg/m2 | S |
| 2026-09-21 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-09-21 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-21 | Heart rate | 74 | /min | S |
| 2026-09-21 | Respiratory rate | 16 | /min | S |
| 2026-09-21 | Body temperature | 36.6 | Cel | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-05-04 | New patient with progressive weakness and loss of coordination: evaluation for a motor neuron disorder and its mimics, safety, and how he wants to receive results | finished | S |
| 2026-05-18 | Neuromuscular neurology consultation with EMG and nerve conduction studies; results of MRI and blood tests; diagnosis and start of treatment | finished | S |
| 2026-06-29 | Six weeks after diagnosis: riluzole safety, genetic test result, multidisciplinary ALS clinic, mobility, mood, and his decision about work | finished | S |
| 2026-08-24 | Three months after diagnosis: ALSFRS-R, breathing, weight, speech, mobility equipment, and work accommodations | finished | S |
| 2026-10-19 | Five months after diagnosis: breathing tests and noninvasive ventilation planning, nutrition and gastrostomy discussion, and his new desk work | finished | S |
| 2026-07-20 | Same-day sick visit for a left ankle sprain | finished | S |
| 2026-09-21 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Evaluation of progressive weakness with mixed upper and lower motor neuron signs: blood count, metabolic panel with calcium, creatine kinase, vitamin B12, TSH, A1c, serum protein electrophoresis with immunofixation, and an HIV test; MRI of the brain and cervical spine; seated spirometry | completed | GL-GOLDCOAST-2020, GL-ELESCORIAL-2000, GL-AAN-ALS-CARE-2009 | S |
| Neuromuscular neurology consultation with EMG and nerve conduction studies for progressive weakness with mixed upper and lower motor neuron signs | completed | GL-GOLDCOAST-2020, GL-AAN-ALS-CARE-2009 | S |
| Safety while the evaluation proceeds: no competitive play or heavy lifting, a physical therapy assessment of balance and gait, home fall precautions (night lights, rails, no loose rugs), and a same-day call for any trouble swallowing or breathing; results given to him first, in person | completed | GL-AAN-ALS-CARE-2009 | S |
| Riluzole 50 mg twice daily, with ALT monthly for the first 3 months and then every 3 months, and a blood count with any fever; genetic testing with genetic counseling for ALS-associated genes, with tofersen only if an SOD1 variant is found; edaravone discussed as an option with modest evidence in a selected group | completed | GL-AAN-ALS-DRUG-2009, GL-ALS-GENETICS-2023, GL-TOFERSEN-2022 | S |
| Multidisciplinary ALS clinic every 2 to 3 months (neurology, nursing, physical, occupational and speech therapy, nutrition, respiratory therapy, social work and mental health): ALSFRS-R, seated forced vital capacity and maximal inspiratory pressure, and weight at every visit; cognitive and behavioral screening; PHQ-9 | completed | GL-AAN-ALS-CARE-2009, GL-ALSFRSR-1999 | S |
| Respiratory plan: forced vital capacity and maximal inspiratory pressure every visit, supine capacity and overnight oximetry when values fall or symptoms appear; noninvasive ventilation when forced vital capacity is below 50% of predicted, maximal inspiratory pressure is weaker than -60 cmH2O, overnight oximetry shows desaturation, or orthopnea or morning headaches appear; influenza and COVID-19 vaccines | completed | GL-AAN-ALS-DRUG-2009, GL-CDC-IMZ-2026 | S |
| Nutrition, speech, swallowing and mobility: a high-calorie diet to keep weight stable, with gastrostomy discussed early, while forced vital capacity is above 50%; speech and swallowing assessments every visit and voice banking; a left ankle-foot orthosis, a cane, and an early power wheelchair evaluation because of lead times; home and car adaptations | completed | GL-AAN-ALS-DRUG-2009, GL-AAN-ALS-CARE-2009 | S |
| Work and planning: workplace accommodations for a desk role (accessible office, flexible hours, rest breaks, voice-recognition software, parking), information on disability benefits, social work support, and early advance care planning, revisited at each change | completed | GL-AAN-ALS-CARE-2009 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| A clear diagnosis, with mimics excluded, within four weeks | 2026-05-18 | completed | Diagnosis made at two weeks on EMG, MRI and blood tests | S |
| No falls, using an ankle-foot orthosis, a cane, and a safer home | 2026-10-19 | active | One fall with an ankle sprain in July, on a day the orthosis was not worn; no falls since it has been worn for all walking outdoors | S |
| Weight held within 5% of the weight at diagnosis | 2026-10-19 | completed | 89.2 kg at diagnosis and 86.6 kg at five months (2.9% lower) | S |
| Breathing tracked every visit, with noninvasive ventilation started as soon as criteria are met | 2026-10-19 | active | FVC 72% and no symptoms at five months; overnight oximetry ordered | S |
| Goals of care, a health care agent, and his wishes about ventilation and feeding recorded early and revisited | 2026-09-21 | completed | Agent named and wishes recorded at the preventive visit | S |
| Working in a role that suits him, with accommodations | 2026-10-19 | completed | Started a desk role in public service with accommodations | S |